aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Personal Genome Diagnostics Inc. (PGDx) was founded with the mission to empower the fight against cancer through advanced genome analysis. The company focuses on providing comprehensive genomic insights for human tumors, primarily for research purposes. Their flagship product, the PGDx elio tissue complete test, offers rapid and actionable genomic profiling for patients with advanced cancer, analyzing over 500 solid tumor-related genes and identifying various somatic mutations. PGDx aims to revolutionize cancer treatment by enabling precise and personalized therapeutic strategies.
Notable figures affiliated with PGDx include co-founders Dr. Victor Velculescu and Dr. Luis Diaz, both renowned for their contributions to cancer genomics. The company has attracted significant investment from entities like New Enterprise Associates (NEA). Key achievements include the FDA clearance and CE-IVD marking of their comprehensive tumor profiling kit, making it a pioneering solution in the market. PGDx's impact lies in its ability to provide highly accurate genomic data, thereby facilitating more effective and personalized cancer treatments worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Genomic Analysis
Technology
Analytics
Tags
Biotech, Data
Model Types
Data Information, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Research
Geographic Exposure
United States
When was Personal Genome Diagnostics founded?
Personal Genome Diagnostics was founded in 2010.
Where is Personal Genome Diagnostics’s headquarters located?
Personal Genome Diagnostics’s headquarters is located in Baltimore, MD, US.
When was Personal Genome Diagnostics’s last funding round?
Personal Genome Diagnostics’s most recent funding round was for $103M (USD) in February 2021.
How many employees does Personal Genome Diagnostics have?
Personal Genome Diagnostics has 179 employees as of Feb 5, 2024.
How much has Personal Genome Diagnostics raised to-date?
As of July 05, 2023, Personal Genome Diagnostics has raised a total of $244.7M (USD) since Feb 10, 2021.
Add Comparison
Total Raised to Date
$244.7M
USD
Last Update Feb 10, 2021
Last Deal Details
$103M
USD
Feb 10, 2021
Series C
Total Employees Over Time
179
As of Feb 2024
Personal Genome Diagnostics Address
2809 Boston Street
Baltimore,
Maryland
21224
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts